EGFR and non-small cell lung carcinoma: A recent report on data from 1,157 patients with advanced NSCLC in the UK indicated that approximately 25% of patients in whom targetable EGFR variants were reported did not receive targeted therapy initially [27]; one potential explanation noted was lengthy EGFR variant test turnaround times [27].